奥拉西坦联合尼莫地平治疗血管性痴呆的疗效观察

Clinical effect of oxiracetam combined with nimodipine in the treatment of vascular dementia

目的探讨奥拉西坦联合尼莫地平治疗血管性痴呆临床应用效果。方法对照组在常规治疗基础上加用尼莫地平;研究组在常规治疗基础上加用尼莫地平联合奥拉西坦治疗,两组血管性痴呆患者均连续治疗3周,记录其临床疗效及药物相关不良反应发生情况。结果治疗前,两组患者简易智能精神状态检查量表(MMSE)评分差异无统计学意义(P>0.05);治疗后,两组MMSE评分均较之前显著提高,研究组精神状态改善效果更优(P<0.05);研究组药物相关不良反应发生率(11.11%)与对照组(6.67)对比并无显著差异(P>0.05)。结论利用尼莫地平联合奥拉西坦治疗,可使血管性痴呆患者获得更为理想的精神状态改善效果,有利于保障其生活质量及身心健康。

Objective To investigate the clinical effect on vascular dementia of oxiracetam combined with nimodipine. Methods The control group were treated with nimodipine, and the patients of Study Group were treated on the basis of conventional therapy plus nimodipine and oxiracetam. Two groups of patients with vascular dementia were treated continuously for 3 week. The adverse reactions and its clinical efficacy would be recorded and analyzed. Results There was no significant difference between the study group and the control group in the aspect of MMSE score before the treatment(P > 0.05). After the treatment, the MMSE scores of the two groups were significantly increased compared to the previous state, and the study group was better( P < 0.05). The rate of Adverse drug reactions of the study group( 11.11%)had no significant difference with that of the control group( 6.67%)( P > 0.05). Conclusion The therapy of Nimodipine combined oxiracetam can make MMSE improved, which is conducive to the protection of the quality of life, physical and mentalhealth.